Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors.
about
Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Long-term clinical benefit fro ...... ts with EGFR wild-type tumors.
@en
Long-term clinical benefit fro ...... ts with EGFR wild-type tumors.
@nl
type
label
Long-term clinical benefit fro ...... ts with EGFR wild-type tumors.
@en
Long-term clinical benefit fro ...... ts with EGFR wild-type tumors.
@nl
prefLabel
Long-term clinical benefit fro ...... ts with EGFR wild-type tumors.
@en
Long-term clinical benefit fro ...... ts with EGFR wild-type tumors.
@nl
P2093
P2860
P1476
Long-term clinical benefit fro ...... ts with EGFR wild-type tumors.
@en
P2093
A G Pallis
A Kalikaki
A Kotsakis
A Koutsopoulos
A Voutsina
E K Dermitzaki
E Kontopodis
E Lagoudaki
E Tsakalaki
P2860
P2888
P304
P356
10.1007/S12094-017-1702-6
P577
2017-06-19T00:00:00Z